Shots:

• The two companies will develop and launch precision medicine strategies for CV- renal- and metabolic diseases. The first stage in the collaboration will use KidneyIntelX to improve outcomes for patients with CKD and its complications- in coordination with the Mount Sinai Health System
• The first stage will assess the impact of AI-enabled in vitro diagnostic solutions to optimize the utilization of therapies in CKD under current SOC protocols. The study will evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalemia with its anticipated results in 2021
• The studies will be conducted in coordination with the Mount Sinai Health System- where KidneyIntelX testing and care management software are currently being deployed for commercial clinical use

­ Ref: PRNewswire | Image: Renalytixa